Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regen BioPharma (RGBPP) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Regen BioPharma (RGBPP) over the last 13 years, with Q3 2025 value amounting to -$572469.0.

  • Regen BioPharma's Income from Continuing Operations fell 11143.98% to -$572469.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 million, marking a year-over-year decrease of 9072.07%. This contributed to the annual value of -$1.3 million for FY2025, which is 9072.09% down from last year.
  • Regen BioPharma's Income from Continuing Operations amounted to -$572469.0 in Q3 2025, which was down 11143.98% from -$167292.0 recorded in Q2 2025.
  • Regen BioPharma's 5-year Income from Continuing Operations high stood at -$13047.0 for Q1 2021, and its period low was -$572469.0 during Q3 2025.
  • Its 5-year average for Income from Continuing Operations is -$182475.5, with a median of -$128529.0 in 2022.
  • In the last 5 years, Regen BioPharma's Income from Continuing Operations skyrocketed by 8924.9% in 2021 and then crashed by 81250.86% in 2022.
  • Regen BioPharma's Income from Continuing Operations (Quarter) stood at -$141432.0 in 2021, then plummeted by 240.25% to -$481226.0 in 2022, then skyrocketed by 69.88% to -$144932.0 in 2023, then tumbled by 255.6% to -$515384.0 in 2024, then decreased by 11.08% to -$572469.0 in 2025.
  • Its Income from Continuing Operations stands at -$572469.0 for Q3 2025, versus -$167292.0 for Q2 2025 and -$19354.0 for Q1 2025.